Ana Morales
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Morales has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Ray Hershberger
The Davis Heart and Lung Research Institute, The Ohio State University
3 shared publications Amy R. Shikany
Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
2 shared publicationsBrittney Murray
Division of Cardiology, Johns Hopkins University, Baltimore, MD, USA
2 shared publicationsChristi Munn
GeneDx, Gaithersburg, MD, USA
2 shared publicationsCrystal Tichnell
Division of Cardiology, Johns Hopkins University, Baltimore, MD, USA
2 shared publicationsDawn C. Allain
Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
2 shared publications
Latest Publications
- 21 May 2019
- Published by Wiley in Journal of Genetic Counseling
- Vol. 28 (4) , 897-907
Communication pitfalls in interpreted genetic counseling sessions
The impact of language interpretation on interactive communication in genetic counseling sessions is not well studied. We sought to determine whether interpretation affects communication in genetic counseling sessions using communication analysis. With a sample of pregnant patients of advanced maternal age, we audiotaped, analyzed, and compared seven Spanish‐speaking patients with limited‐English proficiency to seven English‐speaking patients on length of session, English words spoken, and number of questions asked. An analysis of verbal listening cues, including back‐channels and questions asked was performed to evaluate the level of engagement by both provider and patient. Session length did not differ between groups (p > 0.05), however, English‐speaking sessions involved significantly more words (mean: 4,798 vs. 2,524) exchanged over the course of the conversation than interpreter‐mediated sessions (p < 0.001). The number of back‐channeling responses was significantly greater in English‐speaking compared to Spanish‐speaking sessions. We found the same information was covered, but there was less provider–patient interaction when the session was interpreter‐mediated. The patient asked fewer questions and the genetic counselor spoke in condensed ideas. Overall, our observations suggest diminished levels of interactive communication in interpreter‐mediated sessions. Our work highlights the need for further evaluation in how genetic counselors communicate during interpreter‐mediated sessions.
- 21 May 2019
- Published by Wiley in Journal of Genetic Counseling
- Vol. 28 (4) , 897-907
Communication pitfalls in interpreted genetic counseling sessions
The impact of language interpretation on interactive communication in genetic counseling sessions is not well studied. We sought to determine whether interpretation affects communication in genetic counseling sessions using communication analysis. With a sample of pregnant patients of advanced maternal age, we audiotaped, analyzed, and compared seven Spanish‐speaking patients with limited‐English proficiency to seven English‐speaking patients on length of session, English words spoken, and number of questions asked. An analysis of verbal listening cues, including back‐channels and questions asked was performed to evaluate the level of engagement by both provider and patient. Session length did not differ between groups (p > 0.05), however, English‐speaking sessions involved significantly more words (mean: 4,798 vs. 2,524) exchanged over the course of the conversation than interpreter‐mediated sessions (p < 0.001). The number of back‐channeling responses was significantly greater in English‐speaking compared to Spanish‐speaking sessions. We found the same information was covered, but there was less provider–patient interaction when the session was interpreter‐mediated. The patient asked fewer questions and the genetic counselor spoke in condensed ideas. Overall, our observations suggest diminished levels of interactive communication in interpreter‐mediated sessions. Our work highlights the need for further evaluation in how genetic counselors communicate during interpreter‐mediated sessions.
- 1 June 2018
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 11 (6) , e002169
Variants of Uncertain Significance
- 1 June 2018
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 11 (6) , e002169
Variants of Uncertain Significance
- 1 January 2018
- Published by Elsevier
List of Contributors
- 1 January 2018
- Published by Elsevier
- p. 743-748
Genetic Testing
- 23 October 2017
- Published by Springer Nature in Current Heart Failure Reports
- Vol. 14 (6) , 543-553
Clinical Application of Genetic Testing in Heart Failure
The purpose of this review is to present our current understanding of the genetic etiologies that may cause or predispose to heart failure. We highlight known phenotypes for which a genetic evaluation has clinical utility.
- 23 October 2017
- Published by Springer Nature in Current Heart Failure Reports
- Vol. 14 (6) , 543-553
Clinical Application of Genetic Testing in Heart Failure
The purpose of this review is to present our current understanding of the genetic etiologies that may cause or predispose to heart failure. We highlight known phenotypes for which a genetic evaluation has clinical utility.
- 4 May 2017
- Published by Wiley in Journal of Genetic Counseling
- Vol. 26 (4) , 689
Erratum to: At the Heart of the Pregnancy: What Prenatal and Cardiovascular Genetic Counselors Need to Know about Maternal Heart Disease
- 4 May 2017
- Published by Wiley in Journal of Genetic Counseling
- Vol. 26 (4) , 689
Erratum to: At the Heart of the Pregnancy: What Prenatal and Cardiovascular Genetic Counselors Need to Know about Maternal Heart Disease
- 10 March 2017
- Published by Wiley in Journal of Genetic Counseling
- Vol. 26 (4) , 669-688
At the Heart of the Pregnancy: What Prenatal and Cardiovascular Genetic Counselors Need to Know about Maternal Heart Disease
In the last decade, an increasing number of cardiac conditions have been shown to have a genetic basis. Cardiovascular genetic counseling has emerged as a subspecialty aiming to identify unaffected at‐risk individuals. An important sector of this at‐risk population also includes expectant mothers, in whom unique clinical challenges may arise. Genetic counselors, especially those in cardiovascular and prenatal settings, have an opportunity to identify and assist women who may benefit from cardiovascular care during pregnancy. This paper provides basic management and genetic evaluation principles for affected women, as well as guidance on identifying those who are at risk. We provide considerations for cardiac surveillance in pregnancy and the post‐partum period. Finally, key psychosocial issues that appraise how to best provide support to at risk women as they make informed decisions are discussed. We propose that a team approach including cardiology, maternal fetal medicine, and genetic counseling best serves this patient population. Ongoing questions addressing an evidence based approach to cardiovascular genetic conditions in pregnancy still remain. Thus, well‐designed research protocols are essential to mark progress in this area.
- 10 March 2017
- Published by Wiley in Journal of Genetic Counseling
- Vol. 26 (4) , 669-688
At the Heart of the Pregnancy: What Prenatal and Cardiovascular Genetic Counselors Need to Know about Maternal Heart Disease
In the last decade, an increasing number of cardiac conditions have been shown to have a genetic basis. Cardiovascular genetic counseling has emerged as a subspecialty aiming to identify unaffected at‐risk individuals. An important sector of this at‐risk population also includes expectant mothers, in whom unique clinical challenges may arise. Genetic counselors, especially those in cardiovascular and prenatal settings, have an opportunity to identify and assist women who may benefit from cardiovascular care during pregnancy. This paper provides basic management and genetic evaluation principles for affected women, as well as guidance on identifying those who are at risk. We provide considerations for cardiac surveillance in pregnancy and the post‐partum period. Finally, key psychosocial issues that appraise how to best provide support to at risk women as they make informed decisions are discussed. We propose that a team approach including cardiology, maternal fetal medicine, and genetic counseling best serves this patient population. Ongoing questions addressing an evidence based approach to cardiovascular genetic conditions in pregnancy still remain. Thus, well‐designed research protocols are essential to mark progress in this area.
- 19 May 2013
- Published by Springer Nature in Current Cardiology Reports
- Vol. 15 (7) , 1-8
Genetic Evaluation of Dilated Cardiomyopathy
Recent advances have expanded our ability to conduct a comprehensive genetic evaluation for dilated cardiomyopathy (DCM). By evaluating recent literature, this review aims to bring the reader up-to-date on the genetic evaluation of DCM. Updated guidelines have been published. Mutations in BAG3, including a large deletion, were identified in 2 % of DCM. Truncating mutations in TTN were reported in 25 % of DCM. Two new genes have been reported with autosomal recessive DCM. These studies illustrate the role of improved technologies while raising the possibility of a complex genetic model for DCM. The inclusion of TTN has led to an increased genetic testing detection rate of 40 %. While our ability to identify disease-causing variants has increased, so has the identification of variants of unknown significance. A genetic evaluation for DCM must therefore address this complexity.
- 19 May 2013
- Published by Springer Nature in Current Cardiology Reports
- Vol. 15 (7) , 1-8
Genetic Evaluation of Dilated Cardiomyopathy
Recent advances have expanded our ability to conduct a comprehensive genetic evaluation for dilated cardiomyopathy (DCM). By evaluating recent literature, this review aims to bring the reader up-to-date on the genetic evaluation of DCM. Updated guidelines have been published. Mutations in BAG3, including a large deletion, were identified in 2 % of DCM. Truncating mutations in TTN were reported in 25 % of DCM. Two new genes have been reported with autosomal recessive DCM. These studies illustrate the role of improved technologies while raising the possibility of a complex genetic model for DCM. The inclusion of TTN has led to an increased genetic testing detection rate of 40 %. While our ability to identify disease-causing variants has increased, so has the identification of variants of unknown significance. A genetic evaluation for DCM must therefore address this complexity.